Form 4: AEON Biopharma's Chief Medical Officer, Chad Oh, Receives Stock Options

Chad Oh, Chief Medical Officer of AEON Biopharma, was granted stock options for 86,720 shares on March 19, 2024.

Summary

• This is a Form 4 filing indicating a change in beneficial ownership for Chad Oh, the Chief Medical Officer of AEON Biopharma, Inc.
• On March 19, 2024, Chad Oh was granted stock options for 86,720 shares of AEON Biopharma.
• The exercise price of these stock options is $14.40.
• The options vest in equal installments over four years from the grant date, contingent upon continued service.
• The options expire on March 18, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, used to incentivize performance and retain key personnel.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer to drive company success.
• Employees may see this as a sign of investment in leadership and the company's future.

Key Dates

Keywords

stock options, Form 4, beneficial ownership, AEON Biopharma, Chad Oh, Chief Medical Officer, equity, compensation